

**Supplementary Table S1.** Socio-demographic characteristics of the study cohort, concomitant comorbidity, and current medication

Variable	All N = 514 (%)	CAD <sup>1</sup> N = 116 (22.6%)	Non-CAD N = 398 (77.4%)	P-value
Age (mean)	64.9 ±11.27	69.3 ±8.04	62.8 ±11.66	< 0.001
Age ≤ 50 years	63 (12.3)	0 (0.0)	63 (15.8)	< 0.001
Age ≥ 65 years	292 (56.8)	87 (75.0)	205 (51.5)	< 0.001
Age ≥ 75 years	83 (16.1)	28 (24.1)	55 (13.8)	0.008
Female sex	211 (41.1)	32 (27.6)	179 (45.0)	0.001
Education degree:				
Elementary school	67 (13.0)	23 (19.8)	44 (11.1)	0.014
High school	268 (52.1)	46 (39.7)	222 (55.8)	0.002
College	69 (13.4)	22 (19.0)	47 (11.8)	0.047
University	109 (21.2)	24 (20.7)	85 (21.4)	0.877
Employment status:				
Employed	143 (27.8)	13 (11.2)	130 (32.7)	< 0.001
Unemployed	45 (8.8)	6 (5.2)	39 (9.8)	0.121
Retired	326 (63.4)	97 (83.6)	229 (57.5)	< 0.001
Marital status:				
Married/living with a partner	376 (73.2)	83 (71.6)	293 (73.6)	0.659
Alone/divorced	55 (10.7)	7 (6.0)	48 (12.1)	0.065
Widow(er)	83 (16.1)	26 (22.4)	57 (14.3)	0.037
Cigarette smoking:				
Smoker	94 (18.3)	20 (17.2)	74 (18.6)	0.740
Former smoker	150 (29.2)	52 (44.8)	98 (24.6)	< 0.001
Non-smoker	270 (52.5)	44 (37.9)	226 (56.8)	< 0.001
Functional mobility:				
Fully mobile	483 (94.0)	102 (87.9)	381 (95.7)	0.002
Mobile with help	31 (6.0)	14 (12.1)	17 (4.3)	0.002
Immobile	0 (0.0)	–	–	–
AF characteristics:				
AF	331 (64.4)	58 (50.0)	273 (68.6)	< 0.001
Total AF history [years]	6.41 ±6.63	6.47 ±8.00	6.40 ±6.32	0.948
Duration of AF ≤ 1 year	55 (10.7)	12 (21.4)	43 (16.0)	0.323
Duration of AF ≤ 2 years	103 (20.0)	20 (35.7)	83 (30.9)	0.477
Duration of AF ≤ 3 years	145 (28.2)	26 (46.4)	119 (44.2)	0.764
Permanent AF	97 (18.9)	21 (36.2)	76 (27.8)	0.204
Comorbid conditions:				
Hypertension	418 (81.3)	104 (89.7)	314 (78.9)	0.009
Heart failure	51 (9.9)	24 (20.7)	27 (6.8)	< 0.001
LVEF < 50%	72 (14.0)	36 (31.0)	36 (9.0)	< 0.001
Cardiomyopathy	34 (6.6)	5 (4.3)	29 (7.3)	0.256
Valvular disease	42 (8.2)	12 (10.3)	30 (7.5)	0.331
Supraventricular arrhythmias	84 (16.3)	16 (13.8)	68 (17.1)	0.399
Ventricular arrhythmias	69 (13.4)	19 (16.4)	50 (12.6)	0.289
CIEDs <sup>2</sup>	32 (6.2)	7 (6.0)	25 (6.3)	0.923
Peripheral artery disease	12 (2.3)	6 (5.2)	6 (1.5)	0.021
Diabetes mellitus type II	122 (23.7)	39 (33.6)	83 (20.9)	0.004
Prior stroke/TIA	23 (4.5)	7 (6.0)	16 (4.0)	0.356

Supplementary Table SI. Cont.

Variable	All N = 514 (%)	CAD <sup>1</sup> N = 116 (22.6%)	Non-CAD N = 398 (77.4%)	P-value
CKD	52 (10.1)	24 (20.7)	28 (7.0)	< 0.001
COPD	43 (8.4)	14 (12.1)	29 (7.3)	0.102
Malignancy	27 (5.3)	8 (6.9)	19 (4.8)	0.367
Thyroid dysfunction <sup>3</sup>	94 (18.2)	20 (17.2)	74 (18.6)	0.740
Hyperlipoproteinaemia	208 (40.5)	80 (69.0)	128 (32.2)	< 0.001
Other diseases	91 (17.7)	17 (14.7)	74 (18.6)	0.407
CHA <sub>2</sub> DS <sub>2</sub> -VASc score (mean)	2.71 ±1.51 (range: 0--7)	4.00 ±1.21	2.33 ±1.37	< 0.001
CHA <sub>2</sub> DS <sub>2</sub> -VASc score ≥ 2 points	401 (78.0)	115 (99.1)	286 (71.9)	< 0.001
CHA <sub>2</sub> DS <sub>2</sub> -VASc score ≥ 4 points	157 (30.5)	77 (66.4)	80 (20.1)	< 0.001
Current medication:				
OAC	320 (62.3)	62 (57.8)	253 (63.6)	0.277
OAC treatment duration [years]	3.71 ±3.91	3.79 ±4.57	3.69 ±3.73	0.854
OAC treatment duration ≤ 1 year	100 (19.5)	24 (38.7)	76 (31.1)	0.257
OAC treatment duration ≤ 2 years	154 (30.0)	32 (51.6)	122 (50.0)	0.821
OAC treatment duration ≤ 3 years	194 (37.7)	39 (62.9)	155 (63.5)	0.928
OAC treatment duration ≥ 1 year	233 (76.1)	46 (74.2)	187 (76.6)	0.687
OAC treatment duration ≥ 2 years	193 (63.1)	33 (53.2)	160 (65.6)	0.072
OAC treatment duration ≥ 3 years	152 (49.7)	30 (48.4)	122 (50.0)	0.821
VKA	206 (40.1)	51 (44.0)	155 (38.9)	0.332
NOAC	114 (22.2)	16 (13.8)	98 (24.6)	0.013
LMWH	8 (1.6)	5 (4.7)	3 (0.8)	0.017
Aspirin	118 (23.0)	69 (59.5)	49 (12.3)	< 0.001
P2Y12 inhibitor	69 (13.4)	56 (48.3)	13 (3.3)	< 0.001
B-blocker	396 (77.0)	98 (84.5)	298 (74.9)	0.030
Non-DHP Ca blocker	11 (2.1)	0 (0.0)	11 (2.8)	0.070
Digitalis	17 (3.3)	5 (4.3)	12 (3.0)	0.492
Antiarrhythmic drugs	235 (45.7)	43 (37.1)	192 (48.2)	0.034
Mexiletine	4 (0.8)	0 (0.0)	4 (1.0)	0.278
Propafenone	51 (9.9)	2 (1.7)	49 (12.3)	0.001
Flecainide	32 (6.2)	0 (0.0)	32 (8.0)	0.002
Sotalol	6 (0.9)	2 (1.7)	4 (1.0)	0.526
Amiodarone	145 (61.7)	39 (33.6)	106 (26.6)	0.141
DHP Ca blocker	160 (31.1)	37 (31.9)	123 (30.9)	0.839
ACEI/ARB	359 (69.8)	93 (80.2)	266 (66.8)	0.006
Diuretic	277 (53.9)	79 (68.1)	198 (49.7)	< 0.001
Spironolactone	110 (21.4)	41 (35.3)	69 (17.3)	< 0.001
Statin	226 (44.0)	97 (83.6)	129 (32.4)	< 0.001
Nitrates	45 (8.8)	36 (31.0)	9 (2.3)	< 0.001
Trimetazidine	78 (15.2)	51 (44.0)	27 (6.8)	< 0.001
Sedative	72 (14.0)	21 (18.1)	51 (12.8)	0.149
PPI	147 (28.6)	63 (54.3)	84 (21.1)	< 0.001
Thyroid hormone	56 (10.9)	15 (12.9)	41 (10.3)	0.424
Thyroid suppression therapy	14 (2.7)	1 (0.9)	13 (3.3)	0.162
Insulin	43 (8.4)	19 (16.4)	24 (6.0)	< 0.001
Oral antidiabetic drug	95 (18.5)	27 (23.3)	68 (17.1)	0.131
Other medications	234 (45.5)	85 (73.3)	149 (37.4)	< 0.001

Supplementary Table SI. Cont.

Variable	All N = 514 (%)	CAD <sup>1</sup> N = 116 (22.6%)	Non-CAD N = 398 (77.4%)	P-value
Non-pharmacological treatment:				
Ablation/ECV	141 (27.4)	10 (8.6)	131 (32.9)	< 0.001
ECV AF	96 (18.7)	6 (5.2)	90 (22.6)	< 0.001
ECV AFL	5 (1.0)	0 (0.0)	5 (1.3)	0.225
Ablation AF	55 (10.7)	3 (2.6)	52 (13.1)	0.001
Ablation AFL	12 (2.3)	3 (2.6)	9 (2.3)	0.838
Ablation other arrhythmias	4 (0.8)	0 (0.0)	4 (1.0)	0.278
Multimorbidity and polypharmacy:				
Polypharmacy	353 (68.7)	112 (96.6)	241 (60.6)	< 0.001
N of drugs	6.20 ±2.94	8.91 ±2.84	5.41 ±2.46	< 0.001
N of pills	7.13 ±3.47	10.18 ±3.51	6.24 ±2.91	< 0.001
Parenteral drugs use	50 (9.7)	23 (19.8)	27 (6.8)	< 0.001
N of parenteral applications daily	0.27 ±0.91	9.61 ±3.51	5.61 ±2.83	< 0.001
N of comorbidities	3.59 ±1.67	4.92 ±1.38	3.20 ±1.54	< 0.001
Multimorbidity (without SA/VA)	462 (89.9)	116 (100.0)	346 (86.9)	< 0.001
QoL EQ-5D questionnaire				
Q1 – Mobility	0.83 ±1.10	1.22 ±1.20	0.71 ±1.05	< 0.001
Q2 – Self-care	0.19 ±0.66	0.31 ±0.88	0.16 ±0.58	0.076
Q3 – Usual activities	0.45 ±0.96	0.66 ±1.11	0.39 ±0.90	0.018
Q4 – Pain/discomfort	0.71 ±0.98	0.78 ±1.09	0.69 ±0.95	0.355
Q5 – Anxiety/depression	0.93 ±1.07	0.93 ±1.09	0.93 ±1.06	0.974
QoL EQ-5D total score	3.11 ±3.29	3.90 ±3.72	2.88 ±3.12	0.003
Overall self-rated health status today (range: 0–100)	61.73 ±20.56	55.28 ±21.59	63.61 ±18.88	< 0.001

ACS – acute coronary syndrome, MI – myocardial infarction, CAD – coronary artery disease, LVEF – left ventricular ejection fraction, TIA – transient ischaemic attack, COPD – chronic obstructive pulmonary disease, CKD – chronic kidney disease, PAD – peripheral artery disease, OAC – oral anticoagulant therapy, VKA – vitamin K antagonist, NOAC – non-vitamin K antagonist oral anticoagulant, DHP – dihydropyridine, ACEi – angiotensin-converting enzyme inhibitor, ARB – angiotensin receptor inhibitor, PPI – proton pump inhibitor, Q – question. <sup>1</sup>Coronary artery disease: acute coronary syndrome, n = 13, prior myocardial infarction, n = 61, percutaneous coronary intervention/balloon angioplasty, n = 66, coronary artery bypass grafting, n = 20, chronic stable CAD, n = 28. <sup>2</sup>CIED: cardiac implantable electronic devices (anti-bradycardia pacemaker: n = 20, ICD: n = 7, CRT: n = 5). <sup>3</sup>Thyroid dysfunction: hypothyroidism, n = 65, hyperthyroidism, n = 29.

Supplementary Table SII. Univariate analyses of treatment burden in patients with coronary artery disease

Variable	CAD n = 116 (22.6%) Total TBN				CAD n = 116 (22.6%) TBN ≥ 59 points				CAD n = 116 (22.6%) TBN ≤ 26 points			
	β	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
Age [years]	-0.025	-0.057-0.43	0.787	0.989	0.93-1.05	0.713	0.999	0.95-1.05	0.961			
Age ≤ 40 years	-	-	-	-	-	-	-	-	-	-	-	-
Age ≤ 45 years	-	-	-	-	-	-	-	-	-	-	-	-
Age ≤ 47 years	-	-	-	-	-	-	-	-	-	-	-	-
Age ≤ 48 years	-	-	-	-	-	-	-	-	-	-	-	-
Age ≤ 49 years	-	-	-	-	-	-	-	-	-	-	-	-
Age ≤ 50 years	-	-	-	-	-	-	-	-	-	-	-	-
Age ≤ 64 years	0.029	-7.77-10.60	0.761	1.158	0.41-3.31	0.785	1.161	0.49-2.77	0.737			
Age ≥ 65 years	-0.029	-10.60-7.77	0.761	0.864	0.30-2.47	0.785	0.861	0.36-2.06	0.737			
Age 65-74 years	-0.006	-8.2-7.72	0.952	1.200	0.47-3.05	0.701	0.879	0.41-1.88	0.740			
Age ≥ 75 years	-0.022	-10.41-8.18	0.812	0.648	0.20-2.11	0.471	1.022	0.42-2.48	0.963			
Age ≥ 80 years	0.001	-13.52-13.64	0.993	0.944	0.19-4.71	0.944	0.661	0.166-2.64	0.588			
Female sex	0.123	-2.91-14.76	0.187	1.667	0.62-4.46	0.309	0.636	0.26-1.55	0.317			
Education degree:												
Elementary	-0.055	-12.91-7.02	0.559	0.877	0.27-2.90	0.830	0.970	0.37-2.53	0.950			
High school	-0.003	-8.26-8.00	0.975	0.842	0.32-2.20	0.726	1.535	0.71-3.33	0.278			
College	-0.018	-11.15-9.15	0.846	1.332	0.43-4.11	0.618	1.056	0.40-2.78	0.912			
University	0.085	-5.31-14.26	0.367	1.161	0.38-3.55	0.793	0.543	0.20-1.50	0.238			
Employment status:												
Employed	0.056	-8.81-16.37	0.553	1.326	0.33-5.29	0.689	0.793	0.23-2.75	0.715			
Unemployed	0.044	-13.72-22.17	0.642	2.250	0.39-13.15	0.368	0.910	0.16-5.20	0.916			
Retired	-0.074	-14.98-6.46	0.433	0.595	0.19-1.87	0.375	1.223	0.43-3.50	0.708			
Marital status:												
Married/living with a partner	-0.177	-17.10-0.26	0.057	0.495	0.19-1.30	0.155	1.673	0.69-4.05	0.254			
Alone/divorced	0.173	-086-32.05	0.063	3.553	0.73-17.19	0.115	0.718	0.13-3.88	0.700			
Widow(er)	0.093	-4.73-14.27	0.322	1.387	0.48-4.01	0.545	0.607	0.23-1.59	0.311			

Supplementary Table SII. Cont.

Variable	CAD n = 116 (22.6%) Total TBN			CAD n = 116 (22.6%) TBN ≥ 59 points			CAD n = 116 (22.6%) TBN ≤ 26 points		
	β	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
Cigarette smoking:									
Smoker	0.012	-9.86-11.1	0.899	2.143	0.72-6.42	0.173	1.273	0.47-3.42	0.633
Former smoker	0.084	-4.33-11.61	0.367	0.821	0.32-2.11	0.682	0.810	0.38-1.75	0.590
Non-smoker	-0.096	-12.40-3.93	0.306	0.719	0.27-1.93	0.513	1.074	0.49-2.35	0.858
Functional mobility:									
Fully mobile	0.111	-19.46-4.82	0.235	0.536	0.15-1.90	0.334	3.714	0.79-17.49	0.097
Mobile with help	0.111	-4.82-19.46	0.235	1.867	0.53-6.62	0.334	0.269	0.06-1.27	0.097
Immobile	-	-	-	-	-	-	-	-	-
AF characteristics:									
AF	0.006	-7.70-8.22	0.949	1.000	0.40-2.53	1.000	0.587	0.27-1.27	0.176
Total AF history [years]	0.045	-0.58-0.81	0.739	0.983	0.90-1.08	0.714	0.973	0.89-1.06	0.541
Duration of AF ≤ 1 year	-0.217	-23.66-2.44	0.109	-	-	-	1.500	0.38-5.97	0.565
Duration of AF ≤ 2 years	-0.215	-20.19-2.17	0.112	0.137	0.02-1.16	0.068	1.885	0.56-6.31	0.304
Duration of AF ≤ 3 years	-0.180	-18.06-3.58	0.185	0.359	0.08-1.53	0.166	1.460	0.45-4.79	0.532
Permanent AF	0.187	-3.18-18.85	0.160	2.560	0.67-9.74	0.168	0.434	0.12-1.56	0.202
Comorbid conditions:									
Hypertension	0.014	-12.05-14.08	0.878	1.190	0.24-5.87	0.830	0.741	0.22-2.50	0.629
Heart failure	-0.052	-12.58-7.03	0.576	1.161	0.38-3.55	0.793	1.125	0.44-2.86	0.804
LVEF < 50%	-0.139	-14.95-2.08	0.137	1.046	0.39-2.84	0.930	1.484	0.66-3.34	0.341
Ischaemic heart disease:									
Recent ACS	-0.050	-16.57-9.52	0.594	0.840	0.17-4.14	0.830	1.971	0.59-6.56	0.269
Prior MI	-0.018	-8.76-7.17	0.844	0.880	0.35-2.23	0.787	1.450	0.67-3.13	0.344
Chronic stable CAD	-0.020	-10.44-8.39	0.829	0.686	0.21-2.24	0.532	0.891	0.36-2.21	0.803
PCI/balloon angioplasty	0.084	-4.36-11.65	0.370	1.413	0.54-3.69	0.479	1.109	0.51-2.40	0.792
CABG	-0.003	-10.70-10.36	0.974	1.549	0.50-4.84	0.452	2.097	0.79-5.56	0.137

Supplementary Table SII. Cont.

Variable	CAD n = 116 (22.6%) Total TBN				CAD n = 116 (22.6%) TBN ≥ 59 points				CAD n = 116 (22.6%) TBN ≤ 26 points			
	β	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
Cardiomyopathy	-0.082	-28.19-10.86	0.381	-	-	-	2.882	0.46-17.99	0.257	-	-	-
Valvular disease	-0.009	-13.70-12.42	0.923	1.491	0.37-6.04	0.575	1.971	0.59-6.56	0.269	-	-	-
Supraventricular arrhythmias (SA + AFL)	-0.163	-21.52-1.24	0.080	-	-	-	1.510	0.52-4.41	0.451	-	-	-
Ventricular arrhythmias	-0.095	-16.20-5.20	0.311	0.453	0.10-2.12	0.315	1.081	0.39-3.00	0.881	-	-	-
CIEDs	-0.080	-23.87-9.44	0.393	0.698	0.08-6.12	0.746	1.401	0.30-6.59	0.669	-	-	-
Anti-bradycardia pacemaker	0.034	-20.42-29.68	0.715	2.190	0.19-25.30	0.530	-	-	-	-	-	-
ICD	-0.120	-50.17-10.51	0.198	-	-	-	-	-	-	-	-	-
CRT	-0.068	-41.68-19.31	0.469	-	-	-	1.850	0.11-30.37	0.667	-	-	-
Peripheral artery disease	-0.005	-18.48-17.45	0.955	0.848	0.09-7.64	0.883	0.350	0.04-3.10	0.346	-	-	-
Diabetes mellitus type II	0.331	7.07-22.97	<0.001	3.778	1.44-9.89	0.007	0.344	0.14-0.85	0.020	-	-	-
Prior stroke/TIA	-0.158	-30.70-2.29	0.091	-	-	-	2.595	0.55-12.21	0.228	-	-	-
Chronic kidney disease	-0.088	-14.45-5.12	0.347	0.822	0.25-2.71	0.747	1.749	0.70-4.36	0.231	-	-	-
COPD	0.012	-11.39-13.03	0.894	0.683	0.14-3.30	0.636	0.703	0.21-2.40	0.573	-	-	-
Malignancy	0.130	-4.55-26.59	0.164	2.811	0.62-12.78	0.181	-	-	-	-	-	-
Thyroid dysfunction	0.001	-10.46-10.60	0.989	1.083	0.32-3.63	0.897	0.982	0.36-2.70	0.972	-	-	-
Hyperlipoproteinemia	0.095	-4.14-12.98	0.309	1.250	0.45-3.51	0.672	0.953	0.42-2.17	0.908	-	-	-
Other conditions	0.083	-6.20-16.22	0.378	3.920	1.29-11.91	0.016	1.338	0.47-3.83	0.587	-	-	-
CHA <sub>2</sub> DS <sub>2</sub> -VASC score	0.064	-2.16-4.42	0.496	1.156	0.79-1.69	0.456	0.869	0.63-1.20	0.391	-	-	-
CHA <sub>2</sub> DS <sub>2</sub> -VASC score ≥ 1 point	-	-	-	-	-	-	-	-	-	-	-	-
CHA <sub>2</sub> DS <sub>2</sub> -VASC score ≥ 2 points	0.085	-23.22-62.54	0.366	-	-	-	-	-	-	-	-	-
CHA <sub>2</sub> DS <sub>2</sub> -VASC score ≥ 3 points	0.006	-13.14-14.02	0.949	1.059	0.21-5.29	0.944	1.512	0.38-6.04	0.558	-	-	-
CHA <sub>2</sub> DS <sub>2</sub> -VASC score ≥ 4 points	0.181	-0.087-16.48	0.052	2.669	0.84-8.53	0.097	0.356	0.16-0.80	0.012	-	-	-
CHA <sub>2</sub> DS <sub>2</sub> -VASC score ≥ 5 points	0.028	-7.29-9.90	0.765	1.347	0.51-3.57	0.549	0.608	0.26-1.43	0.255	-	-	-
CHA <sub>2</sub> DS <sub>2</sub> -VASC score ≥ 6 points	-0.009	-13.70-12.42	0.923	0.840	0.17-4.14	0.830	1.971	0.59-6.56	0.269	-	-	-

Supplementary Table SIII. Cont.

Variable	CAD n = 116 (22.6%) Total TBN				CAD n = 116 (22.6%) TBN ≥ 59 points				CAD n = 116 (22.6%) TBN ≤ 26 points			
	β	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
Current medication:												
OAC	-0.022	-9.00-7.10	0.815	0.851	0.33-2.17	0.735	0.567	0.26-1.23	0.149			
OAC treatment duration [years]	-0.079	-1.46-0.77	0.540	1.010	0.88-1.16	0.888	1.089	0.97-1.22	0.147			
OAC treatment duration ≤ 1 year	-0.066	-13.06-7.75	0.612	0.255	0.05-1.28	0.097	0.722	0.23-2.28	0.579			
OAC treatment duration ≤ 2 years	-0.121	-14.85-5.33	0.349	0.133	0.03-0.67	0.015	0.667	0.22-2.01	0.471			
OAC treatment duration ≤ 3 years	-0.032	-11.80-9.22	0.807	0.515	0.14-1.84	0.307	0.647	0.21-1.98	0.445			
OAC treatment duration ≥ 1 year	0.291	1.99-24.19	0.022	-	-	-	0.588	0.18-1.97	0.389			
OAC treatment duration ≥ 2 years	0.141	-4.53-15.62	0.275	5.870	1.17-29.57	0.032	1.141	0.38-3.44	0.814			
OAC treatment duration ≥ 3 years	0.121	-5.33-14.85	0.349	7.500	1.48-37.91	0.015	1.500	0.50-4.52	0.471			
VKA	0.014	-7.42-8.61	0.884	1.077	0.42-2.74	0.876	0.625	0.29-1.3	0.238			
NOAC	-0.051	-14.70-8.34	0.586	0.571	0.12-2.72	0.482	0.808	0.26-2.51	0.712			
LMWH	-0.042	-24.06-15.09	0.651	1.071	0.11-10.09	0.952	2.882	0.46-17.99	0.257			
ASA	-0.013	-8.67-7.53	0.890	1.241	0.48-3.24	0.660	1.101	0.51-2.40	0.809			
P <sub>2</sub> Y12 inhibitor	-0.051	-10.14-5.76	0.586	0.870	0.34-2.21	0.769	0.887	0.41-1.90	0.758			
β-blocker	0.035	-8.89-13.08	0.706	1.203	0.32-4.58	0.787	0.281	0.10-0.80	0.017			
Non-DHP Ca blocker	-	-	-	-	-	-	-	-	-			
Digitalis	0.005	-19.06-20.12	0.957	1.071	0.11-10.09	0.952	0.444	0.05-4.11	0.474			
Antiarrhythmic drugs	-0.161	-15.27-0.99	0.085	0.578	0.21-1.61	0.294	1.335	0.61-2.92	0.469			
Mexiletine	-	-	-	-	-	-	-	-	-			
Propafenone	-0.043	-37.65-23.42	0.645	-	-	-	-	-	-			
Flecainide	-	-	-	-	-	-	-	-	-			
Sotalol	0.040	-23.92-37.16	0.668	4.429	0.27-73.70	0.300	1.850	0.11-30.37	0.667			
Amiodarone	-0.164	-15.73-0.89	0.079	0.519	0.18-1.53	0.235	1.447	0.65-3.21	0.363			
DHP Ca blocker	-0.073	-11.85-5.17	0.439	0.411	0.13-1.32	0.134	1.172	0.52-2.64	0.701			
ACEI/ARB	0.072	-6.09-13.82	0.443	1.712	0.46-6.37	0.423	1.317	0.49-3.52	0.583			

Supplementary Table S11. Cont.

Variable	CAD n = 116 (22.6%) Total TBN				CAD n = 116 (22.6%) TBN ≥ 59 points				CAD n = 116 (22.6%) TBN ≤ 26 points			
	β	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
Diuretic	-0.106	-1336-3.61	0.258	0.613	0.24-1.60	0.316	1.208	0.53-2.76	0.654	1.208	0.53-2.76	0.654
Spirolactone	-0.241	-18.87-(-2.72)	0.009	0.342	0.11-1.09	0.070	1.769	0.80-3.89	0.156	1.769	0.80-3.89	0.156
Statin	0.062	-7.12-14.34	0.507	1.299	0.34-4.92	0.700	0.925	0.33-2.57	0.881	0.925	0.33-2.57	0.881
Nitrates	0.112	-3.34-13.75	0.230	2.179	0.84-5.65	0.109	1.050	0.46-2.39	0.908	1.050	0.46-2.39	0.908
Trimetazidine	0.143	-1.74-14.12	0.125	3.452	1.28-9.28	0.014	0.854	0.40-1.85	0.688	0.854	0.40-1.85	0.688
Sedative	0.230	2.78-22.89	0.013	4.731	1.67-13.43	0.004	0.897	0.33-2.44	0.831	0.897	0.33-2.44	0.831
PPI	0.066	-5.12-10.82	0.480	2.054	0.77-5.49	0.152	0.960	0.45-2.06	0.917	0.960	0.45-2.06	0.917
Thyroid hormone	0.071	-7.26-16.39	0.446	1.677	0.48-5.87	0.419	0.903	0.29-2.85	0.861	0.903	0.29-2.85	0.861
Thyroid suppression therapy	-0.102	-66.50-19.11	0.275	-	-	-	-	-	-	-	-	-
Insulin	0.281	5.96-26.60	0.002	4.312	1.48-12.60	0.008	0.291	0.08-1.07	0.063	0.291	0.08-1.07	0.063
Oral antidiabetic drug	0.133	-2.59-16.08	0.155	1.727	0.62-4.81	0.296	0.441	0.16-1.20	0.109	0.441	0.16-1.20	0.109
Other medications	0.063	-5.93-12.02	0.502	1.813	0.56-5.85	0.320	0.992	0.42-2.34	0.985	0.992	0.42-2.34	0.985
Non-pharmacological treatment:												
Ablation/ECV	-0.162	-26.34-1.63	0.083	-	-	-	3.043	0.81-11.49	0.101	3.043	0.81-11.49	0.101
ECV AF	-0.096	-27.19-8.57	0.305	-	-	-	1.895	0.37-9.85	0.447	1.895	0.37-9.85	0.447
ECV AFL	-	-	-	-	-	-	-	-	-	-	-	-
Ablation AF	-0.179	-48.78-0.55	0.055	-	-	-	-	-	-	-	-	-
Ablation AFL	-0.092	-37.44-12.48	0.324	-	-	-	3.795	0.33-43.17	0.282	3.795	0.33-43.17	0.282
Ablation other arrhythmias	-	-	-	-	-	-	-	-	-	-	-	-
Multimorbidity and polypharmacy:												
Polypharmacy	0.055	-15.31-28.23	0.558	-	-	-	0.534	0.07-3.94	0.539	0.534	0.07-3.94	0.539
N of drugs	0.075	-0.84-1.97	0.426	1.137	0.96-1.35	0.135	0.950	0.83-1.09	0.459	0.950	0.83-1.09	0.459
N of pills	-0.022	-1.27-1.00	0.817	1.060	0.93-1.21	0.390	0.998	0.90-1.11	0.975	0.998	0.90-1.11	0.975
N of drugs without OAC	0.043	-1.12-1.78	0.649	1.115	0.94-1.33	0.220	0.983	0.86-1.13	0.810	0.983	0.86-1.13	0.810
N of pills without OAC	-0.019	-1.25-1.02	0.842	1.063	0.93-1.21	0.365	1.010	0.91-1.13	0.863	1.010	0.91-1.13	0.863
Parenteral drugs use	0.184	0.10-19.72	0.048	3.010	1.08-8.42	0.036	0.585	0.21-1.62	0.303	0.585	0.21-1.62	0.303

Supplementary Table SII. Cont.

Variable	CAD n = 116 (22.6%) Total TBN			CAD n = 116 (22.6%) TBN ≥ 59 points			CAD n = 116 (22.6%) TBN ≤ 26 points		
	β	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
N of parenteral applications daily	0.203	0.36–6.64	0.029	1.384	1.01–1.90	0.046	0.765	0.53–1.11	0.160
N of comorbidities	0.043	-2.22–3.57	0.645	1.147	0.82–1.60	0.418	0.907	0.68–1.20	0.496
Multimorbidity (without SAVVA)	–	–	–	–	–	–	–	–	–
QoL EQ-5D questionnaire									
Q1 – Mobility	0.146	-0.68–5.91	0.119	1.179	0.80–1.73	0.400	0.640	0.45–0.91	0.012
Q2 – Self-care	0.195	0.33–9.25	0.036	1.593	1.03–2.47	0.038	–	–	–
Q3 – Usual activities	0.144	-0.77–6.35	0.123	1.466	1.01–2.14	0.046	0.711	0.48–1.06	0.091
Q4 – Pain/discomfort	0.085	-1.97–5.31	0.364	1.340	0.90–1.99	0.148	0.873	0.61–1.25	0.459
Q5 – Anxiety/depression	0.381	4.16–10.97	< 0.001	1.822	1.20–2.77	0.005	0.463	0.29–0.74	0.001
QoL EQ-5D total score	0.272	0.54–2.61	0.003	1.161	1.04–1.30	0.011	0.788	0.68–0.92	0.003
Overall self-rated health status today (range: 0–100)	-0.188	-0.37–(-0.01)	0.043	0.990	0.97–1.01	0.372	1.032	1.01–1.05	0.003

AF – atrial fibrillation, LVEF – left ventricular ejection fraction, ACS – acute coronary syndrome, MI – myocardial infarction, CAD – coronary artery disease, PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting, AFL – atrial flutter, CIED – cardiac implantable electronic devices, ICD – implantable cardioverter defibrillator, CRT – cardiac resynchronisation therapy, TIA – transient ischaemic attack, COPD – chronic obstructive pulmonary disease, OAC – oral anticoagulant therapy, VKA – vitamin K antagonist, NOAC – non-vitamin K antagonist oral anticoagulant, ASA – acetylsalicylic acid, DHP – diltiazem, ACEI – angiotensin converting enzyme inhibitor, ARB – angiotensin receptor inhibitor, PPI – proton pump inhibitor, ECV – electrical cardioversion, SA – supraventricular arrhythmias, VA – ventricular arrhythmias, N – number.

Supplementary Table SIII. Univariate analyses of treatment burden in patients without coronary artery disease

Variable	Total TBN						Non-CAD					
	TBN ≥ 59 points			TBN ≤ 26 points			TBN ≥ 59 points			TBN ≤ 26 points		
	β	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
Age [years]	-0.112	-0.44-(-0.03)	0.025	0.981	0.96-0.999	0.044	1.018	0.97-1.04	0.092			
Age ≤ 40 years	0.101	0.31-22.0	0.044	2.072	0.82-5.23	0.123	0.350	0.08-1.54	0.165			
Age ≤ 45 years	0.103	0.40-16.50	0.040	2.390	1.20-4.76	0.013	0.588	0.24-1.45	0.251			
Age ≤ 47 years	0.111	0.96-16.04	0.027	2.561	1.34-4.89	0.004	0.703	0.32-1.57	0.391			
Age ≤ 48 years	0.086	-0.87-13.43	0.085	2.233	1.20-4.15	0.011	0.798	0.38-1.67	0.548			
Age ≤ 49 years	0.073	-1.78-11.86	0.147	1.819	0.997-3.32	0.051	0.678	0.33-1.40	0.296			
Age ≤ 50 years	0.175	-2.01-11.00	0.175	1.768	0.993-3.15	0.053	0.573	0.28-1.18	0.129			
Age ≤ 64 years	0.061	-1.81-7.69	0.224	1.273	0.81-2.00	0.298	0.750	0.47-1.20	0.228			
Age ≥ 65 years	-0.061	-7.69-1.81	0.224	0.786	0.50-1.24	0.298	1.334	0.84-2.13	0.228			
Age 65-74 years	-0.025	-6.17-3.64	0.612	0.908	0.57-1.45	0.687	1.262	0.79-2.03	0.335			
Age ≥ 75 years	-0.053	-10.56-3.21	0.294	0.713	0.35-1.44	0.347	1.141	0.59-2.20	0.694			
Age ≥ 80 years	-0.005	-10.69-9.69	0.923	1.055	0.40-2.75	0.913	1.168	0.45-3.06	0.751			
Female sex	0.189	4.46-13.85	< 0.001	2.256	1.42-3.58	0.001	0.675	0.42-1.09	0.105			
Education degree:												
Elementary	-0.066	-12.64-2.50	0.189	0.633	0.28-1.41	0.264	1.830	0.94-3.58	0.078			
High school	0.057	-1.99-7.57	0.252	1.668	1.04-2.67	0.033	1.066	0.67-1.70	0.788			
College	0.098	1.00-14.67	0.050	1.307	0.67-2.56	0.434	0.642	0.29-1.43	0.277			
University	-0.097	-11.45-0.10	0.054	0.469	0.25-0.89	0.020	0.780	0.43-1.41	0.409			
Employment status:												
Employed	-0.050	-7.66-2.47	0.315	0.903	0.56-1.47	0.682	0.915	0.56-1.51	0.728			
Unemployed	0.019	-6.45-9.55	0.704	1.031	0.48-2.20	0.938	0.694	0.30-1.63	0.402			
Retired	0.036	-304-6.58	0.469	1.084	0.68-1.72	0.732	1.224	0.76-1.97	0.403			
Marital status:												
Married/living with a partner	-0.107	-11.23-(-0.50)	0.032	0.570	0.35-0.93	0.025	1.303	0.75-2.25	0.343			
Alone/divorced	0.066	-2.41-12.17	0.189	1.583	0.83-3.03	0.165	1.107	0.55-2.23	0.776			
Widow(er)	0.074	-1.71-11.84	0.142	1.605	0.88-2.94	0.125	0.574	0.27-1.22	0.148			

Supplementary Table SIII. Cont.

Variable	Total TBN						Non-CAD					
	TBN ≤ 26 points			TBN ≥ 59 points			TBN ≤ 26 points			TBN ≥ 59 points		
	β	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
Cigarette smoking:												
Smoker	0.010	-5.51-6.72	0.845	1.036	0.58-1.85	0.904	1.067	0.59-1.93	0.829			
Former smoker	0.019	-4.48-6.56	0.712	0.956	0.56-1.62	0.867	1.348	0.80-2.27	0.261			
Non-smoker	-0.024	-5.96-3.64	0.636	1.012	0.64-1.60	0.960	0.761	0.48-1.21	0.251			
Functional mobility:												
Fully mobile	-0.101	-23.75-(-0.35)	0.044	0.358	0.13-0.96	0.040	1.443	0.41-5.14	0.571			
Mobile with help	0.101	0.35-23.75	0.044	2.792	1.05-7.45	0.040	0.693	0.20-2.47	0.571			
Immobile	-	-	-	-	-	-	-	-	-			
AF characteristics:												
AF	0.124	1.37-11.54	0.013	2.017	1.18-3.45	0.010	0.614	0.38-0.995	0.048			
Total AF history [years]	0.042	-0.31-0.65	0.489	1.033	0.99-1.08	0.118	0.977	0.93-1.03	0.383			
Duration of AF ≤ 1 year	-0.060	-12.44-4.18	0.329	0.442	0.19-1.04	0.062	2.115	1.03-4.35	0.042			
Duration of AF ≤ 2 years	-0.023	-7.89-5.32	0.702	0.737	0.41-1.33	0.313	1.612	0.87-2.98	0.127			
Duration of AF ≤ 3 years	-0.040	-8.16-4.12	0.517	0.605	0.35-1.05	0.072	1.341	0.74-2.42	0.330			
Permanent AF	-0.022	-8.00-5.49	0.715	0.835	0.46-1.51	0.553	0.365	0.16-0.81	0.014			
Comorbid conditions:												
Hypertension	-0.044	-8.45-3.20	0.376	0.688	0.40-1.17	0.167	0.823	0.47-1.43	0.492			
Heart failure	-0.040	-13.29-5.62	0.425	0.842	0.33-2.15	0.719	1.708	0.74-3.94	0.209			
LVEF < 50%	-0.090	-15.83-0.68	0.072	0.570	0.23-1.41	0.225	1.293	0.60-2.79	0.513			
Cardiomyopathy	-0.012	-10.26-8.04	0.811	1.147	0.49-2.68	0.751	0.946	0.33-2.14	0.724			
Valvular disease	0.023	-6.95-11.06	0.654	1.815	0.83-3.96	0.134	1.449	0.64-3.28	0.374			
Supraventricular arrhythmias (SA + AFL)	-0.092	-12.17-0.41	0.067	0.523	0.26-1.04	0.065	1.898	1.08-3.35	0.027			
Ventricular arrhythmias	-0.105	-14.74-(-0.47)	0.037	0.530	0.24-1.17	0.117	1.844	0.97-3.49	0.060			
CIEDs	0.111	1.30-20.79	0.026	2.507	1.10-5.72	0.029	0.429	0.13-1.47	0.177			
Anti-bradycardia pacemaker	0.095	-0.39-23.00	0.058	2.792	1.05-7.45	0.040	0.196	0.03-1.50	0.117			
ICD	0.050	-10.56-32.10	0.322	0.742	0.08-6.72	0.791	0.818	0.09-7.410	0.858			
CRT	0.026	-20.27-34.71	0.606	6.061	0.54-67.57	0.143	1.647	0.15-18.37	0.685			

Supplementary Table SIII. Cont.

Variable	Total TBN						Non-CAD					
	$\beta$	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
Peripheral artery disease	0.021	-15.46-23.57	0.683	0.592	0.07-5.13	0.634	0.652	0.08-5.65	0.698			
Diabetes mellitus type II	0.084	-0.87-10.80	0.095	1.486	0.87-2.53	0.145	0.738	0.40-1.35	0.324			
Prior stroke/TIA	-0.039	-16.83-7.37	0.442	0.678	0.19-2.43	0.551	0.749	0.21-2.69	0.657			
Chronic kidney disease	0.019	-7.52-11.08	0.707	0.993	0.41-2.41	0.987	0.526	0.18-1.56	0.246			
COPD	0.142	4.11-22.23	0.004	2.634	1.22-5.69	0.014	0.665	0.25-1.80	0.421			
Malignancy	0.042	-6.3515.94	0.398	1.068	0.78-3.04	0.902	0.602	0.17-2.11	0.428			
Thyroid dysfunction	0.065	-2.07-10.13	0.195	1.229	0.70-2.16	0.475	0.802	0.43-1.49	0.486			
Hyperlipoproteinaemia	-0.042	-7.26-2.92	0.402	0.931	0.57-1.52	0.774	1.216	0.75-1.98	0.434			
Other conditions	0.022	-5.02-7.85	0.665	1.172	0.65-2.13	0.602	0.791	0.41-1.53	0.484			
CHA <sub>2</sub> DS <sub>2</sub> -VASC score	0.021	-1.3-2.10	0.680	1.024	0.67-1.21	0.778	0.960	0.81-1.14	0.642			
CHA <sub>2</sub> DS <sub>2</sub> -VASC score $\geq$ 1 point	0.035	-4.79-9.95	0.492	1.112	0.54-2.28	0.772	0.772	0.39-1.53	0.460			
CHA <sub>2</sub> DS <sub>2</sub> -VASC score $\geq$ 2 points	-0.090	-9.22-0.42	0.073	0.611	0.39-0.96	0.034	1.130	0.70-1.82	0.615			
CHA <sub>2</sub> DS <sub>2</sub> -VASC score $\geq$ 3 points	-0.078	-9.32-1.06	0.119	0.735	0.44-1.23	0.241	1.516	0.93-2.48	0.097			
CHA <sub>2</sub> DS <sub>2</sub> -VASC score $\geq$ 4 points	-0.020	-10.56-6.93	0.684	0.822	0.34-1.96	0.659	0.445	0.15-1.30	0.139			
CHA <sub>2</sub> DS <sub>2</sub> -VASC score $\geq$ 5 points	0.045	-8.28-22.09	0.372	2.028	0.56-7.34	0.281	0.357	0.05-2.86	0.332			
CHA <sub>2</sub> DS <sub>2</sub> -VASC score $\geq$ 6 points	0.033	-31.61-63.36	0.511	-	-	-	-	-	-			
Current medication:												
OAC	0.098	-0.02-9.82	0.051	1.560	0.96-2.55	0.076	0.696	0.43-1.12	0.133			
OAC treatment duration (years)	0.119	-0.04-1.68	0.063	1.073	0.998-1.15	0.055	0.892	0.80-0.99	0.037			
OAC treatment duration $\leq$ 1 year	-0.096	-12.24-1.67	0.136	0.549	0.29-1.05	0.071	1.953	1.03-3.69	0.039			
OAC treatment duration $\leq$ 2 years	-0.097	-11.43-1.46	0.129	0.583	0.33-1.03	0.064	1.927	1.02-3.63	0.043			
OAC treatment duration $\leq$ 3 years	-0.088	-11.37-2.03	0.171	0.617	0.35-1.10	0.099	1.899	0.95-3.80	0.070			
OAC treatment duration $\geq$ 1 year	0.108	-1.08-14.13	0.092	2.061	0.97-4.36	0.059	0.464	0.24-0.91	0.026			
OAC treatment duration $\geq$ 2 years	0.092	-1.83-11.73	0.152	1.619	0.87-3.01	0.128	0.508	0.27-0.95	0.034			
OAC treatment duration $\geq$ 3 years	0.097	-1.46-11.43	0.129	1.716	0.97-3.04	0.064	0.519	0.28-0.98	0.043			
VKA	0.175	3.83-13.44	< 0.001	2.051	1.30-3.25	0.002	0.689	0.42-1.12	0.132			
NOAC	-0.089	-10.45-0.55	0.078	0.650	0.37-1.14	0.133	1.008	0.59-1.73	0.978			

Supplementary Table SIII. Cont.

Variable	Non-CAD														
	Total TBN					TBN ≥ 59 points					TBN ≤ 26 points				
	β	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
LMWH	-0.040	-38.73-16.22	0.421	1.495	0.13-16.67	0.744	1.647	0.15-18.37	0.685						
ASA	-0.017	-8.45-6.02	0.741	0.846	0.42-1.73	0.645	1.533	0.79-2.96	0.203						
P <sub>2</sub> Y12 inhibitor	0.072	-3.66-23.03	0.154	1.338	0.40-4.44	0.634	0.587	0.13-2.70	0.494						
β-blocker	-0.053	-8.42-2.54	0.292	0.940	0.56-1.58	0.816	1.408	0.80-2.48	0.234						
Non-DHP Ca blocker	0.069	-4.36-24.59	0.170	1.732	0.50-6.05	0.389	-	-	-						
Digitalis	0.044	-7.71-20.08	0.382	2.188	0.68-7.06	0.190	0.291	0.04-2.28	0.240						
Antiarrhythmic drugs	0.048	-2.43-7.08	0.338	1.290	0.82-2.03	0.272	1.066	0.67-1.70	0.788						
Mexiletine	0.012	-20.98-26.70	0.814	0.993	0.10-9.56	0.995	10.133	1.04-98.61	0.046						
Propafenone	-0.041	-10.24-4.23	0.414	0.638	0.30-1.37	0.247	1.713	0.90-3.28	0.104						
Flecainide	0.047	-4.61-12.87	0.353	1.394	0.64-3.05	0.407	0.912	0.38-2.18	0.835						
Sotalol	0.043	-13.39-34.26	0.390	0.993	0.10-9.66	0.995	-	-	-						
Amiodarone	0.053	-2.49-8.26	0.292	1.518	0.93-2.49	0.097	0.815	0.48-1.40	0.459						
DHP Ca blocker	0.052	-2.42-7.86	0.299	1.006	0.62-1.64	0.981	0.626	0.37-1.07	0.086						
ACE/ARB	0.017	-4.18-5.93	0.734	0.951	0.59-1.54	0.838	0.7257	0.45-1.18	0.196						
Diuretic	-0.038	-6.57-2.94	0.454	0.863	0.55-1.36	0.525	0.985	0.62-1.57	0.950						
Spironolactone	0.053	-2.92-9.63	0.294	1.506	0.96-2.65	0.156	0.894	0.48-1.67	0.725						
Statin	0.038	-3.14-7.02	0.453	1.315	0.82-2.11	0.258	0.814	0.49-1.35	0.427						
Nitrates	-0.010	-17.65-14.35	0.839	0.366	0.05-2.96	0.346	0.404	0.05-3.27	0.395						
Trimetazidine	-0.002	-9.64-9.28	0.970	1.277	0.54-3.01	0.577	1.417	0.60-3.35	0.428						
Sedative	0.057	-3.00-11.21	0.257	1.022	0.52-2.01	0.949	0.889	0.44-1.81	0.745						
PPI	0.116	1.04-12.62	0.021	1.681	0.995-2.84	0.052	0.595	0.32-1.12	0.105						
Thyroid hormone	0.019	-6.33-9.32	0.707	1.265	0.62-2.58	0.519	0.914	0.42-1.99	0.821						
Thyroid suppression therapy	0.100	0.19-26.82	0.047	1.908	0.61-5.97	0.267	0.587	0.13-2.70	0.494						
Insulin	0.058	-4.12-15.83	0.250	1.866	0.79-4.41	0.155	1.379	0.55-3.43	0.490						
Oral antidiabetic drug	0.043	-3.55-9.07	0.391	1.192	0.66-2.14	0.557	0.824	0.43-1.56	0.553						
Other medications	0.081	-0.89-8.91	0.108	1.526	0.96-2.42	0.072	0.744	0.46-1.22	0.239						

Supplementary Table SIII. Cont.

Variable	Non-CAD														
	Total TBN					TBN ≥ 59 points					TBN ≤ 26 points				
	β	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
Non-pharmacological treatment:															
Ablation/ECV	-0.077	-8.97-1.12	0.127	0.690	0.42-1.14	0.147	0.845	0.51-1.40	0.147	0.845	0.51-1.40	0.147	0.845	0.51-1.40	0.147
ECV AF	-0.116	-12.34-(-1.05)	0.020	0.577	0.32-1.05	0.070	0.998	0.57-1.74	0.070	0.998	0.57-1.74	0.070	0.998	0.57-1.74	0.070
ECV AFL	-0.016	-24.76-17.94	0.754	-	-	-	-	-	-	-	-	-	-	-	-
Ablation AF	-0.003	-7.30-6.82	0.947	0.992	0.51-1.95	0.982	1.108	0.56-2.18	0.982	1.108	0.56-2.18	0.982	1.108	0.56-2.18	0.982
Ablation AFL	-0.112	-34.03-(-2.24)	0.025	-	-	-	4.276	1.12-16.26	-	4.276	1.12-16.26	-	4.276	1.12-16.26	0.033
Ablation other arrhythmias	-0.008	-25.78-21.91	0.873	0.993	0.10-9.66	0.995	-	-	0.995	-	-	0.995	-	-	-
Multimorbidity and polypharmacy:															
Polypharmacy	0.080	-0.90-8.80	0.110	1.287	0.80-2.06	0.294	0.694	0.43-1.11	0.294	0.694	0.43-1.11	0.294	0.694	0.43-1.11	0.127
N of drugs	0.135	0.37-2.33	0.007	1.107	1.01-1.22	0.032	0.912	0.83-1.01	0.032	0.912	0.83-1.01	0.032	0.912	0.83-1.01	0.076
N of pills	0.111	0.11-1.74	0.027	1.071	0.99-1.16	0.078	0.922	0.85-1.00	0.078	0.922	0.85-1.00	0.078	0.922	0.85-1.00	0.058
N of drugs without OAC	0.119	0.21-2.24	0.018	1.094	0.99-1.20	0.065	0.922	0.83-1.02	0.065	0.922	0.83-1.02	0.065	0.922	0.83-1.02	0.128
N of pills without OAC	0.097	-0.01-1.67	0.052	1.062	0.98-1.15	0.131	0.928	0.85-1.01	0.131	0.928	0.85-1.01	0.131	0.928	0.85-1.01	0.090
Parenteral drugs use	0.041	-5.54-13.36	0.416	1.837	0.81-4.16	0.144	1.417	0.60-3.35	0.144	1.417	0.60-3.35	0.144	1.417	0.60-3.35	0.428
N of parenteral applications daily	0.087	-0.37-5.86	0.084	1.326	1.02-1.73	0.036	0.933	0.73-1.35	0.036	0.933	0.73-1.35	0.036	0.933	0.73-1.35	0.964
N of comorbidities	0.018	-1.27-1.82	0.725	1.026	0.89-1.19	0.727	0.977	0.84-1.14	0.727	0.977	0.84-1.14	0.727	0.977	0.84-1.14	0.762
Multimorbidity (without SA/VA)	0.064	-2.47-11.62	0.202	1.291	0.64-2.62	0.480	0.803	0.41-1.56	0.480	0.803	0.41-1.56	0.480	0.803	0.41-1.56	0.516
QoL EQ-5D questionnaire:															
Q1 – Mobility	0.166	1.58-6.07	0.001	1.283	1.04-1.58	0.018	0.845	0.67-1.07	0.018	0.845	0.67-1.07	0.018	0.845	0.67-1.07	0.163
Q2 – Self-care	0.114	0.68-8.88	0.022	1.389	0.98-1.97	0.066	0.757	0.46-1.24	0.066	0.757	0.46-1.24	0.066	0.757	0.46-1.24	0.268
Q3 – Usual activities	0.112	0.37-5.63	0.026	1.276	1.01-1.61	0.039	0.783	0.58-1.07	0.039	0.783	0.58-1.07	0.039	0.783	0.58-1.07	0.119
Q4 – Pain/discomfort	0.194	2.47-7.40	< 0.001	1.400	1.12-1.76	0.004	0.731	0.55-0.96	0.004	0.731	0.55-0.96	0.004	0.731	0.55-0.96	0.026
Q5 – Anxiety/depression	0.320	5.15-9.41	< 0.001	1.639	1.33-2.02	< 0.001	0.663	0.51-0.85	< 0.001	0.663	0.51-0.85	< 0.001	0.663	0.51-0.85	0.001
QoL EQ-5D total score	0.277	1.40-2.87	< 0.001	1.156	1.08-1.24	< 0.001	0.876	0.80-0.96	< 0.001	0.876	0.80-0.96	< 0.001	0.876	0.80-0.96	0.004
Overall self-rated health status today (range: 0-100)	-0.187	-0.34-(-0.11)	< 0.001	0.980	0.67-0.99	0.001	1.012	1.00-1.02	0.001	1.012	1.00-1.02	0.001	1.012	1.00-1.02	0.059

AF – atrial fibrillation, LVEF – left ventricular ejection fraction, ACS – acute coronary syndrome, MI – myocardial infarction, CAD – coronary artery disease, PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting, AFL – atrial flutter, CIED – cardiac implantable electronic devices, ICD – implantable cardioverter defibrillator, CRT – cardiac resynchronisation therapy, TIA – transient ischaemic attack, COPD – chronic obstructive pulmonary disease, OAC – oral anticoagulant therapy, VKA – vitamin K antagonist, NOAC – non-vitamin K antagonist oral anticoagulant, ASA – acetylsalicylic acid, DHP – dihydropyridine, ACEI – angiotensin converting enzyme inhibitor, ARB – angiotensin receptor inhibitor, PPI – proton pump inhibitor, ECV – electrical cardioversion, SA – supraventricular arrhythmias, VA – ventricular arrhythmias, N – number.

**Supplementary Table SIV.** Multivariable linear and logistic regression analyses of treatment burden in patients without coronary artery disease

<b>Multivariable linear regression analysis</b>			
<b>Variable</b>	<b><math>\beta</math></b>	<b>95% CI</b>	<b>P-value</b>
Q5 – Anxiety/depression	0.264	3.95–8.11	< 0.001
VKA therapy	0.136	1.71–11.69	0.009
Age	–0.215	–0.64–(–0.25)	< 0.001
Female sex	0.146	2.52–11.63	0.002
Number of drugs	0.107	0.13–2.01	0.026
Atrial fibrillation	0.126	0.86–12.25	0.024
<b>Multivariable logistic regression analysis of the highest TBNQ score quartile (<math>\geq 59</math>)</b>			
<b>Variable</b>	<b>OR</b>	<b>95% CI</b>	<b>P-value</b>
Age $\leq 47$ years	4.232	1.91–9.36	< 0.001
Female sex	2.601	1.53–4.41	< 0.001
Atrial fibrillation	2.171	1.10–4.29	0.026
CHA <sub>2</sub> DS <sub>2</sub> -VASc score $\geq 2$ male, $\geq 3$ female	0.427	0.24–0.78	0.005
VKA therapy	1.899	1.07–3.38	0.029
Number of drugs	1.168	1.04–1.30	0.007
Q5 – Anxiety/depression	1.513	1.20–1.90	< 0.001
<b>Multivariable logistic regression analysis of the lowest TBNQ score quartile (<math>\leq 26</math>)</b>			
<b>Variable</b>	<b>OR</b>	<b>95% CI</b>	<b>P-value</b>
Q5 – Anxiety/depression	0.695	0.50–0.97	0.033
Permanent atrial fibrillation	0.345	0.15–0.79	0.011

VKA – vitamin K antagonist, Q – question, TBNQ – Treatment Burden Questionnaire.